Navigation Links
The Leukemia & Lymphoma Society: Impacting Blood Cancers and Beyond
Date:2/19/2013

s as soon as possible. LLS works in concert with academic investigators, medical centers and pharmaceutical and biotechnology companies to move promising therapies quickly from the laboratory into clinical trials and, ultimately, to patients.

LLS continues to support and fund the world's best and brightest academic scientists and award grants based on merit to advance progress in all areas of blood cancer research, and at all stages from basic science to clinical trials. Through our grants programs we support the development of the next generation of first rate cancer researchers.

Proof of LLS's cure-focused, patient-centered infrastructure is apparent from the allocation of its funds. Last year, 78 percent of the money spent by LLS went to research, patient and community services, advocacy and education. Its co-pay assistance program provided $44.2 million to almost 14,000 patients in need. LLS's Office of Public Policy team advocates for policies that help speed the approval process for new blood cancer therapies and ensure access to quality, affordable and coordinated care for patients.

"Ultimately, cancer affects everyone," said Walter. "We all have an opportunity to impact a cure for this disease now. Someday truly is today."

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Key LLS fundraising campaigns include Team In Training, Light The Night, School & Youth, Man & Woman of the Year and Regatta. To reach the widest possible audience, LLS partners with national and regional level companies and brands, including Nike, Disney, Burlington
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia
2. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
3. Inovio Pharmaceuticals Announces Positive Interim Results in Phase II Leukemia Trial
4. Global Acute Myeloid Leukemia (AML) Therapeutics Industry
5. The Leukemia & Lymphoma Society Awards $12 Million in Research Grants in Four Critical Areas of Unmet Medical Need
6. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
7. Study of Cell Therapeutics Tosedostat for Elderly Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now Enrolling
8. Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
9. How Malignant Cells in Patients With Chronic Lymphocytic Leukemia Escape T Cell Recognition and Attack
10. Founder of National Childrens Leukemia Unveiled Non-Embryonic Stem Cell Treatment Promising Cure for Cancer at GIL 2012: Europe
11. Roche Launches 454 Sequencing Assays for High Sensitivity Genetic Variant Detection in Leukemia Samples to Drive Blood Cancer Research Worldwide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 Texas Governor Rick ... Texas A&M Health Science Center CEO Brett Giroir, ... Health and Human Services (HHS), State of Texas ... pandemic influenza vaccine manufacturing facility in Bryan, Texas, ... for the Texas A&M Biocorridor – a rapidly ...
(Date:9/18/2014)... 18, 2014 Research and Markets ... Chinese Stem Cell Industry Report, 2014-2017" report to ... biological cells that can differentiate into specialized cells and ... Stem cell therapy can be applied to treatment of ... nervous system diseases, damage or lesion of liver, kidney ...
(Date:9/18/2014)... -- Research and Markets has announced the ... 2014" report to their offering. ... professional and in-depth study on the current state of ... provides a basic overview of the industry including definitions, ... market analysis is provided for the international markets including ...
(Date:9/18/2014)... 18, 2014 Leatherwood Plastics has ... material, to stay competitive in the semiconductor, clean ... materials ultimately impact product quality and productivity, according ... , Established in 1980 in Lewisville, TX, ... fabricators have left the business. Much of Leatherwood’s ...
Breaking Biology Technology:Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2
... MARLBOROUGH, Mass., July 21, 2011 Advanced Cell Technology, ... of regenerative medicine, announced today that it has entered ... Ltd. ("CHA Biotech"), a leading South Korea-based biotechnology company, ... international joint venture, Stem Cell & Regenerative Medicine International ...
... University Medical Center have discovered a way to block ... responsible for the largest number of sexually transmitted infections ... included Duke University microbiologists and chemists, designed a molecule ... The therapies that could come from this discovery mark ...
... Regulus Therapeutics Inc ., a biopharmaceutical company leading the ... announced that it has identified a third microRNA target ... milestone payment from GSK. This selection represents another significant ... which is focused on the discovery and development of ...
Cached Biology Technology:ACT Obtains Exclusive License for Hemangioblast Technology in North America 2ACT Obtains Exclusive License for Hemangioblast Technology in North America 3ACT Obtains Exclusive License for Hemangioblast Technology in North America 4ACT Obtains Exclusive License for Hemangioblast Technology in North America 5Newly designed molecule blocks chlamydia bacteria 2Newly designed molecule blocks chlamydia bacteria 3Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 2Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 3Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment 4
(Date:9/18/2014)... 2014Many Americans across racial and ethnic groups describe ... on their day-to-day life, more so than other ... speech (57% of African-Americans, 49% of non-Hispanic whites, ... asked which disease or ailment is the worst ... among African-Americans followed by AIDS/HIV. Hispanics and ...
(Date:9/18/2014)... carbon and nitrogen comprise all spheres of our ... have caused imbalances and perturbations that resulted in ... GHGs result in climate changes which influence the ... the atmosphere. Understanding these feedback mechanisms has become ... science during the past three decades. , In ...
(Date:9/18/2014)... probably the ultimate form of camouflage: you don,t just ... strategy is not as uncommon as you might think. ... USA, explains that the larval life stages of many ... of the anatomy that most creatures cannot make transparent. ... to shield each individual eye unit with an opaque ...
Breaking Biology News(10 mins):Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3Greenhouse gas research enters a new era 2Transparent larvae hide opaque eyes behind reflections 2
... may choose their mate with the help of smell. They ... more efficient immune system. This has been shown in a ... a Swedish-French collaboration. Humans and many animals can choose ... right smell can give the offspring an efficient immune system. ...
... Efforts to begin human clinical trials using stem ... a $37.3 million boost from the California Institute for ... on Sept. 5. UC Irvine scientists will ... Team Therapy Development Awards, which are designed to accelerate ...
... genus Hematodinium are a big problem for crab, ... in BioMed Central,s open access journal Aquatic Biosystems ... crangon ), these parasites have bacteria-like endosymbionts. The presence of ... of Hematodinium . Hematodinium sp. and ...
Cached Biology News:State stem cell research funding agency awards $37.3 million to aid UC Irvine efforts 2State stem cell research funding agency awards $37.3 million to aid UC Irvine efforts 3Lifestyle of a killer 2
... jetSI-ENDO-FluoF is a fluorescein-conjugated ... emission at 520 nm), the ... reagents are used to determine ... the intracellular delivery and trafficking ...
... and Tissue Staining Kits are intended for ... of histological and cytological specimens. These kits ... manufactured by either R&D Systems or by ... the formation of the Avidin-Biotin Complex (ABC) ...
... Purification Protocols covers a wide range of ... and experienced researchers in all areas of ... from the books preface illustrates just how ... research library., The chapters introduce the theoretical ...
... TSQ Quantum Ultra defines a new standard ... analysis. It features the revolutionary Ion ... titanium skimmer with superior skimming and larger ... Its redesigned ion transfer tube lens with ...
Biology Products: